• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials
    Get the next $HTGC alert in real time by email

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics

    Brian Hansen to be appointed Chief Commercial Officer

    Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization

    Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time

    GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distribution of Eversense 365 and future products from Ascensia Diabetes Care, a member of PHC Group, to Senseonics.

    Since 2020, Ascensia has held the exclusive worldwide distribution rights for Eversense products, including Eversense 365. Under the terms of the Memorandum of Understanding, Senseonics would assume responsibility for all global sales, marketing and commercialization in the U.S. beginning January 1, 2026, and utilize Transition Service Agreements through Ascensia until fully established in markets outside the U.S. Brian Hansen, President of CGM at Ascensia since February 2024 and former Chief Commercial Officer at Tandem Diabetes Care, would join Senseonics as Chief Commercial Officer on January 1, 2026. The companies are currently working together to develop definitive documentation for the planned transaction.

    As awareness of Eversense continues to grow with the momentum of the Eversense 365 approval, the go-to-market approach is increasingly diverging from Ascensia's core blood glucose monitoring business. Eversense is at an inflection point that requires strategic investment and fully-dedicated commercial efforts, along with tight vertical integration to quickly respond to market needs. By unifying the Eversense business and incorporating commercial activities directly within Senseonics, the companies believe Eversense would achieve accelerated growth and realize its full potential faster than under the current structure.

    Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics stated, "I'm thrilled to bring Eversense 365 commercialization back in-house and directly control investment in growing the brand to better serve the needs of patients and providers. With Brian to remain at the helm of Senseonics' commercialization efforts, we are confident that this move will yield benefits for our customers and our shareholders. Eversense 365 is the world's first and only year-long continuous glucose monitor, deserving a dedicated sales force and commercial infrastructure. We truly appreciate the partnership and investment that PHC Group and Ascensia has made in Senseonics. We look forward to welcoming the talented commercial team to Senseonics to help ensure a positive experience for our customers, while working to accelerate growth of Eversense 365."

    Koichiro Sato, Chief Operating Officer and Chief Strategy Officer of PHC Group and CEO of Ascensia Diabetes Care, commented: "We are very proud to have worked with Senseonics on commercializing Eversense and are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them under the planned agreements. The Eversense long-term CGM system can help overcome many frustrations in diabetes management and we believe in the growth potential of Eversense and remain invested in Senseonics."

    For Senseonics, bringing Eversense commercial sales and operations in-house as planned should position the company to better meet payer, provider and patient needs, as well as improve efficiency and agility. Owning the commercial channel is also expected to increase topline revenue and expand margins by eliminating Ascensia revenue sharing. The investments in the commercial organization would be funded in part by improved margins, but also from the expanded $100 million non-dilutive debt facility with Hercules Capital, Inc. (NYSE:HTGC). Senseonics expects to see immediate revenue improvement and gross margin expansion to 50% in 2026, with a planned increase to more than 70% gross margins at scale.

    Full Year 2025 Financial Outlook

    Senseonics continues to expect full-year 2025 global net revenue to be approximately $34-38 million as we continue to roll out Eversense 365 to U.S. patients. The full-year 2025 financial outlook assumes approximately doubling of our global patient base during 2025, with approximately one-third of revenue generated in the first half of 2025 and two-thirds of revenue to be generated in the second half of 2025. Second half revenue is expected to be weighted to the fourth quarter due to a one-time shift to once-a-year Eversense 365 reorder dynamics following its Q4 2024 launch. The financial outlook takes into consideration current assumptions regarding: (i) refined visibility of the timeline and specifications for the regulatory approval and the plans for commercial transition to Eversense 365 outside the United States, (ii) projected plans with respect to spending on the DTC marketing campaign to generate additional leads, (iii) executing on other sales and marketing initiatives, (iv) anticipated utilization and impact of the patient assistance programs for Eversense 365, and (v) continued progress with the transition of reimbursement from Eversense E3 to Eversense 365. Gross margins are expected to increase throughout 2025, with 2025 gross margins between 32.5% and 37.5% for the full year. Cash used in operations in 2025 is expected to be approximately $60 million.

    Conference Call Details

    Management will host an investor call and live webcast to discuss the commercial transition starting at 8:00 a.m. (Eastern Time), September 4, 2025.

    The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to "Investor Relations," and then "Events & Publications," and will be archived there for future reference. To listen to the conference call, please dial 1-800-579-2543 (US/Canada) or 1-785-424-1789 (International), passcode SENSE365, approximately ten to five minutes prior to start time.

    About Senseonics



    Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

    About Eversense



    The Eversense® Continuous Glucose Monitoring (CGM) Systems are indicated for continually measuring glucose levels for up to 365 days for Eversense® 365 and 180 days for Eversense® E3 in persons with diabetes age 18 and older. The systems are indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time per week after day 14 for Eversense® 365 and one time per day after day 21 for Eversense® E3, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense CGM Systems are prescription devices; patients should talk to their health care provider to learn more. For important safety information, see https://www.eversensediabetes.com/safety-info/.

    Forward Looking Statements

    Any statements in this press release about the expectations regarding the transition of the commercialization responsibility of Eversense 365 from Ascensia to Senseonics, the finalization of definitive documentation for such transition, the smooth transition of the commercial team and operations, the success of the future commercialization of Eversense 365, the financial implications of the transition, including revenue and gross margin projections, and the availability of improved margins to support certain investments, trends of interest in, and market acceptance and adoption of, Eversense 365 by patients and prescribers, revenue expectations, product development plans and/or growth of Eversense, the appointment of Mr. Hansen to serve as the Company's chief commercial officer, the availability of future borrowing under the Hercules debt facility, the expectations for the facility's coverage of costs, the revenue, gross margin, cash flow and global installed customer base projections, and global installed customer base and reorder assumptions, under the heading "Full Year 2025 Financial Outlook," and other statements containing the words "believe," "expect," "intend," "may," "projects," "will," "planned," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including:  uncertainties inherent in the negotiation and finalization of the transition agreements with Ascensia, uncertainties in connection with the transition of the commercial organization from Ascensia to Senseonics, risk related to the ongoing commercialization of Eversense 365, uncertainties in prescriber and patient decisions and responses to new technology or initiatives, uncertainties in insurer, regulatory and administrative processes and decisions, uncertainties inherent in the development and registration of new technology, uncertainties in the development of and competition in the overall CGM market, uncertainties with respect to satisfying conditions to the availability of borrowing capacity under the Company's amended credit facility with Hercules, the potential inability to receive requisite stockholder approval of the Company's recently proposed reverse stock split, and such other factors as are set forth in the risk factors detailed in Senseonics' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent quarterly reports on Form 10-Q filed with the SEC under the heading "Risk Factors" and the Definitive Proxy Statement filed with the SEC on August 18, 2025 under the heading "Certain Risks and Potential Disadvantages Associated with a Reverse Stock Split." In addition, the forward-looking statements included in this press release represent Senseonics' views as of the date hereof. Senseonics anticipates that subsequent events and developments will cause Senseonics' views to change. However, while Senseonics may elect to update these forward-looking statements at some point in the future, Senseonics specifically disclaims any obligation to do so except as required by law. These forward-looking statements should not be relied upon as representing Senseonics' views as of any date subsequent to the date hereof.

    Senseonics Investor Contact

    Jeremy Feffer

    LifeSci Advisors

    [email protected]



    Primary Logo

    Get the next $HTGC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTGC
    $SENS

    CompanyDatePrice TargetRatingAnalyst
    Senseonics Holdings Inc.
    $SENS
    8/27/2025$1.50Overweight
    Barclays
    Senseonics Holdings Inc.
    $SENS
    7/15/2025$1.25Buy
    TD Cowen
    Senseonics Holdings Inc.
    $SENS
    6/2/2025$1.10Buy
    H.C. Wainwright
    Senseonics Holdings Inc.
    $SENS
    4/10/2025$2.00Outperform
    Mizuho
    Hercules Capital Inc.
    $HTGC
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    Hercules Capital Inc.
    $HTGC
    11/21/2023$17.00Neutral
    UBS
    Hercules Capital Inc.
    $HTGC
    8/30/2023$17.50Neutral → Buy
    Compass Point
    More analyst ratings

    $HTGC
    $SENS
    SEC Filings

    View All

    SEC Form EFFECT filed by Senseonics Holdings Inc.

    EFFECT - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/19/25 12:15:16 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form 424B3 filed by Senseonics Holdings Inc.

    424B3 - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/18/25 4:36:27 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form DEF 14A filed by Senseonics Holdings Inc.

    DEF 14A - Senseonics Holdings, Inc. (0001616543) (Filer)

    8/18/25 7:30:29 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    $HTGC
    $SENS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer & CCO Botelho Kiersten Zaza covered exercise/tax liability with 770 shares, decreasing direct ownership by 1% to 65,881 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    7/15/25 5:03:48 PM ET
    $HTGC
    Investment Managers
    Finance

    Chief Operating Officer Follmann Christian covered exercise/tax liability with 829 shares, decreasing direct ownership by 0.69% to 119,423 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    7/15/25 5:03:28 PM ET
    $HTGC
    Investment Managers
    Finance

    Chief Financial Officer Meyer Seth H covered exercise/tax liability with 4,051 shares, decreasing direct ownership by 1% to 377,121 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    7/15/25 5:03:12 PM ET
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $SENS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $HTGC
    $SENS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $HTGC
    $SENS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Barclays initiated coverage on Senseonics with a new price target

    Barclays initiated coverage of Senseonics with a rating of Overweight and set a new price target of $1.50

    8/27/25 8:26:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    TD Cowen initiated coverage on Senseonics with a new price target

    TD Cowen initiated coverage of Senseonics with a rating of Buy and set a new price target of $1.25

    7/15/25 8:44:36 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    H.C. Wainwright resumed coverage on Senseonics with a new price target

    H.C. Wainwright resumed coverage of Senseonics with a rating of Buy and set a new price target of $1.10

    6/2/25 8:54:33 AM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Ascensia Diabetes Care Signs MOU to Transfer Eversense® CGM Distribution to Strategic Partner Senseonics

    - Agreement with Senseonics to transfer commercial activities would integrate Eversense manufacturing and distribution to accelerate growth PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, today announced that Ascensia has signed a memorandum of understanding to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NYSE:SENS). The companies are targeting to unite Eversense R&D, manufacturing, and commercial activities within Senseonics beginning January 1, 2026, subject to a definitiv

    9/3/25 7:22:00 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    Hercules Capital Receives a BBB+ Affirmed Investment Grade Corporate and Credit Rating from Kroll Bond Rating Agency, Inc.

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Kroll Bond Rating Agency, Inc. ("KBRA") has affirmed Hercules' investment grade corporate and credit rating of BBB+. KBRA issued a statement announcing the affirmation of the rating and stable outlook, as well as its underlying analysis. The affirmed BBB+ rating reflects the Company's diversified investment portfolio with a focus on senior secured first lien venture debt investments in the technology

    8/19/25 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    Chief Operating Officer Follmann Christian sold $7,043 worth of shares (395 units at $17.83) and bought $7,043 worth of shares (395 units at $17.83), increasing direct ownership by 0.22% to 121,212 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    6/5/25 6:38:34 PM ET
    $HTGC
    Investment Managers
    Finance

    Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    5/9/25 4:22:23 PM ET
    $HTGC
    Investment Managers
    Finance

    Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    5/9/25 4:22:04 PM ET
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $SENS
    Financials

    Live finance-specific insights

    View All

    Senseonics Signs Memorandum of Understanding with Ascensia Diabetes Care to Take Over Commercialization and Distribution of Eversense 365

    CGM commercial operations to transition from Ascensia Diabetes Care to Senseonics Brian Hansen to be appointed Chief Commercial Officer Non-dilutive debt facility expanded up to $100 million with Hercules Capital to fund commercial organization Conference Call scheduled for September 4, 2025 at 8:00 A.M. Eastern Time GERMANTOWN, Md., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced a mutually executed Memorandum of Understanding to transition all commercialization and distributio

    9/3/25 5:17:09 PM ET
    $HTGC
    $SENS
    Investment Managers
    Finance
    Industrial Machinery/Components
    Industrials

    Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile

    CARY, N.C., Aug. 8, 2025 Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced the completion of a comprehensive capital restructuring designed to enhance the Company's financial flexibility, reduce total debt, and support long-term growth. The multi-faceted refinancing transaction consisted of the following key components: A new senior credit facility with Hercules Capital, Inc. (NYSE:HTGC), due in 2030, which provides $110.0 million in committed capital at closing and an additional $40.0 million in two $20.0 million tranches available upon achievement of certain milestones, to be drawn at the Company's discretion;An exc

    8/8/25 7:45:00 AM ET
    $HRTX
    $HTGC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Managers
    Finance

    Hercules Capital Reports Second Quarter 2025 Financial Results

    Q2 2025 Total Gross Debt and Equity Commitments of $1.0 Billion Record Q2 2025 Total Gross Fundings of $709.1 Million Record 1H 2025 Total Gross Debt and Equity Commitments of $2.02 Billion Record 1H 2025 Total Gross Fundings of $1.25 Billion Record Q2 2025 Net Investment Income "NII" of $88.7 Million Q2 2025 NII of $0.50 per Share provides 125% Coverage of the Base Cash Distribution Closed Upsized Offering of $350.0 Million of 6.000% Unsecured Notes due 2030 Renewed and Increased Its Credit Facility with MUFG Bank, Ltd. to $440.0 Million Conservative Balance Sheet Management with Net GAAP Leverage of 95.0% and Net Regulatory Leverage of 78.7%(1) Inclusive of the Adviser F

    7/31/25 4:07:00 PM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $SENS
    Leadership Updates

    Live Leadership Updates

    View All

    Snappt Acquires Trigo to Enhance Applicant Trust Platform for Multifamily Housing, Secures $50M Growth Financing

    Strategic growth financing accelerates expansion through acquisition and supports product innovation Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifying rental payment history. Backed by a $50 million committed facility from Hercules Capital, Inc. (NYSE:HTGC), the acquisition expands Snappt's platform and strengthens its ability to help property managers make faster, more confident leasing decisions. Together, these milestones mark a major step toward building the industry's most complete and trusted solution embedded into the application and screening process. "This

    8/5/25 12:00:00 PM ET
    $HTGC
    Investment Managers
    Finance

    Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

    SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

    11/29/23 1:01:00 PM ET
    $HTGC
    $TPVG
    Investment Managers
    Finance
    Other Consumer Services
    Consumer Discretionary

    Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

    9/25/23 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $SENS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    2/13/24 5:13:59 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G/A filed by Senseonics Holdings Inc. (Amendment)

    SC 13G/A - Senseonics Holdings, Inc. (0001616543) (Subject)

    7/7/23 4:35:55 PM ET
    $SENS
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by Hercules Capital Inc.

    SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

    5/8/23 5:06:26 PM ET
    $HTGC
    Investment Managers
    Finance